CARsgen Therapeutics (HKG:2171) recorded positive results for the confirmatory phase 2 clinical trial of Satri-cel, a candidate drug for the treatment of gastric, gastroesophageal junction, and pancreatic cancer, a Monday Hong Kong bourse filing said.
The study evaluated the safety and efficacy of satricabtagene autoleucel or satri-cel, CT041 in patients with advanced gastric or gastroesophageal junction cancers.
The study, including the assessment by the Independent Review Committee, showed an elevated progression-free survival rate for the patients treated with satri-cel compared to other treatment choices in the market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。